Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | QPCT | Q16769 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541643 | 0.83 | SCN9A (0.41) | GPR119SCN9ACSF1RALOX5APFEN1 | |
| SCHEMBL584451 | 0.78 | PIK3CA (0.42) | QPCT | |
| SCHEMBL583358 | 0.77 | QPCT (0.37) | QPCT | |
| SCHEMBL2366939 | 0.74 | CPS1 (0.41) | GPR119USP30 | |
| SCHEMBL2366957 | 0.74 | CPS1 (0.41) | GPR119USP30 | |
| SCHEMBL8251060 | 0.74 | L3MBTL1 (0.42) | GPR119USP30 | |
| SCHEMBL15537604 | 0.74 | GPR119 (0.50) | GPR119SCN9ACSF1RALOX5APFEN1 | |
| SCHEMBL13419698 | 0.74 | GPR119 (0.50) | GPR119SCN9ACSF1RALOX5APFEN1 | |
| SCHEMBL2366839 | 0.73 | JAK1 (0.38) | GPR119USP30 | |
| SCHEMBL2366841 | 0.73 | JAK1 (0.38) | GPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124623-B2 | 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-02-28 | — | — | US | disclosed |
| US-20090247578-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE-DERIVATIVES AND THEIR USES AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247578-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE-DERIVATIVES AND THEIR USES AS ANTIBACTERIALS | OGFOD1, OXGR1, ODC1 | GPR119 1093/4885SCN9A 3442/4885CSF1R 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.